An innovative platform trial
Within an innovative platform design study, we will evaluate the efficacy of multiple promising compounds, all of which have been shown to be safe in patients with ALS and have a high potential for therapeutic efficacy. Patients will be randomized into the three treatment arms based on their genetic profile. The primary aim is to assess the efficacy of the drugs versus placebo on overall survival. A large advantage of this design is that we can decrease the chance of being randomized to placebo, namely in a ratio of 2:1 instead of 1:1. In the future, other compounds may be added to this platform study.
Lighthouse – Triumeq treatment arm
Triumeq, a therapy developed for treatment of human immunodeficiency virus (HIV) infection has shown to slow progression on the ALSFRS-R in a Phase IIa trial in 40 patients with ALS, while Triumeq was also demonstrated to be safe and well tolerated. This treatment arm aims to confirm the efficacy of Triumeq as a treatment in patients with ALS in prolonging overall survival time.
Leonard van den BergProfessor of Neurology
Professor Leonard van den Berg is professor of Neurology and coordinator of the ALS Centre Netherlands.
PreLude (Lithium carbonate)
Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.Read more
iAdore (Oral edaravone)
Within an innovative platform design study, we will evaluate the efficacy of oral edaravone (TW001), a formulation that reduces oxidative stressRead more
TRICALS aims to speed up the development of new medicines for ALS. You can help by registering with TRICALS. The participation of patients in clinical trials is necessary to find better treatments.